Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci

被引:47
作者
He, YX
Honnen, WJ
Krachmarov, CP
Burkhart, M
Kayman, SC
Corvalan, J
Pinter, A
机构
[1] Publ Hlth Res Inst, Lab Retroviral Biol, Newark, NJ 07103 USA
[2] Abgenix Inc, Fremont, CA 94555 USA
关键词
D O I
10.4049/jimmunol.169.1.595
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite considerable interest in the isolation of mAbs with potent neutralization activity against primary HIV-1 isolates, both for identifying useful targets for vaccine development and for the development of therapeutically useful reagents against HIV-1 infection, a relatively limited number of such reagents have been isolated to date. Human mAbs (hu-mAbs) are preferable to rodent mAbs for treatment of humans, but isolation of hu-mAbs from HIV-infected subjects by standard methods of EBV transformation of B cells or phage display of Ig libraries is inefficient and limited by the inability to control or define the original immunogen. An alternative approach for the isolation of hu-mAbs has been provided by the development of transgenic mice that produce fully hu-mAbs. In this report, we show that immunizing the XenoMouse G2 strain with native recombinant gp120 derived from HIVSF162 resulted in robust Immoral Ab responses against gp120 and allowed the efficient isolation of hybridomas producing specific hu-mAbs directed against multiple regions and epitopes of gp120. hu-mAbs possessing strong neutralizing activity against the autologous HIVSF162 strain were obtained. The epitopes recognized were located in three previously described neutralization domains, the V2-, V3- and CD4-binding domains, and in a novel neutralization domain, the highly variable C-terminal region of the V1 loop. This is the first report of neutralizing mAbs directed at targets in the VI region. Furthermore, the V2 and V3 epitopes recognized by neutralizing hu-mAbs were distinct from those of previously described human and rodent mAbs and included an epitope requiring a full length V3 loop peptide for effective presentation. These results further our understanding of neutralization targets for primary, R5 HIV-1 viruses and demonstrate the utility of the XenoMouse system for identifying new and interesting epitopes on HIV-1.
引用
收藏
页码:595 / 605
页数:11
相关论文
共 73 条
[61]   CHARACTERIZATION OF CONSERVED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 NEUTRALIZATION EPITOPES EXPOSED UPON GP120-CD4 BINDING [J].
THALI, M ;
MOORE, JP ;
FURMAN, C ;
CHARLES, M ;
HO, DD ;
ROBINSON, J ;
SODROSKI, J .
JOURNAL OF VIROLOGY, 1993, 67 (07) :3978-3988
[62]   SYNERGISTIC NEUTRALIZATION OF HIV-1 BY HUMAN MONOCLONAL-ANTIBODIES AGAINST THE V3 LOOP AND THE CD4-BINDING SITE OF GP120 [J].
TILLEY, SA ;
HONNEN, WJ ;
RACHO, ME ;
CHOU, TC ;
PINTER, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (04) :461-467
[63]   A HUMAN MONOCLONAL-ANTIBODY AGAINST THE CD4-BINDING SITE OF HIV-1 GP120 EXHIBITS POTENT, BROADLY NEUTRALIZING ACTIVITY [J].
TILLEY, SA ;
HONNEN, WJ ;
RACHO, ME ;
HILGARTNER, M ;
PINTER, A .
RESEARCH IN VIROLOGY, 1991, 142 (04) :247-259
[64]   CROSS-CLADE NEUTRALIZATION OF PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY HUMAN MONOCLONAL-ANTIBODIES AND TETRAMERIC CD4-IGG [J].
TRKOLA, A ;
POMALES, AB ;
YUAN, H ;
KORBER, B ;
MADDON, PJ ;
ALLAWAY, GP ;
KATINGER, H ;
BARBAS, CF ;
BURTON, DR ;
HO, DD ;
MOORE, JP .
JOURNAL OF VIROLOGY, 1995, 69 (11) :6609-6617
[65]   Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 [J].
Trkola, A ;
Purtscher, M ;
Muster, T ;
Ballaun, C ;
Buchacher, A ;
Sullivan, N ;
Srinivasan, K ;
Sodroski, J ;
Moore, JP ;
Katinger, H .
JOURNAL OF VIROLOGY, 1996, 70 (02) :1100-1108
[66]   Alterations in the V1/V2 domain of HIV-2CBL24 glycoprotein 105 correlate with an extended cell tropism [J].
Vella, C ;
King, D ;
Zheng, NN ;
Fickenscher, H ;
Breuer, J ;
Daniels, RS .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (15) :1399-1402
[67]   Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site [J].
VijhWarrier, S ;
Pinter, A ;
Honnen, WJ ;
Tilley, SA .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4466-4473
[68]   SEQUENCE DIVERSITY OF V1 AND V2 DOMAINS OF GP120 FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - LACK OF CORRELATION WITH VIRAL PHENOTYPE [J].
WANG, N ;
ZHU, TF ;
HO, DD .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2708-2715
[69]   A NOVEL, GLYCAN-DEPENDENT EPITOPE IN THE V2 DOMAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GYR120 IS RECOGNIZED BY A HIGHLY POTENT, NEUTRALIZING CHIMPANZEE MONOCLONAL-ANTIBODY [J].
WARRIER, SV ;
PINTER, A ;
HONNEN, WJ ;
GIRARD, M ;
MUCHMORE, E ;
TILLEY, SA .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4636-4642
[70]   The antigenic structure of the HIV gp120 envelope glycoprotein [J].
Wyatt, R ;
Kwong, PD ;
Desjardins, E ;
Sweet, RW ;
Robinson, J ;
Hendrickson, WA ;
Sodroski, JG .
NATURE, 1998, 393 (6686) :705-711